Private equity firm Carlyle Group is in exclusive discussions to purchase Baxter International’s kidney care spinoff, Vantive, in a deal valued at around $4bn including debt, according to reports by Reuters and the Wall Street Journal.
The report cites an unnamed source in revealing that the parties entered exclusive negotiations in late June, and an announcement over a deal could be made in the coming weeks.
Shares of Baxter International, based in Deerfield, Illinois, have risen by more than 4% since news of the potential deal broke.
In March, Baxter announced it was exploring the sale of its kidney care unit with select private equity investors. The decision came more than a year after Baxter revealed plans to separate the unit due to supply chain challenges and weak demand for dialysis operations. The company aims to complete the separation in the second half of the year.
Can’t stop reading? Read more
Paramount seeks $24bn Gulf backing to support $110bn Warner takeover
Paramount seeks $24bn Gulf backing to support $110bn Warner takeover Paramount Skydance is in...
Fund Friday: Top fundraising news in private equity
Fund Friday: Top fundraising news in private equity KKR has closed its North America Fund XIV at...
OVS secures $330m financing as TIP-backed retailer strengthens balance sheet
OVS secures $330m financing as TIP-backed retailer strengthens balance sheet OVS has secured a...